CJC-1295 with DAC: A Laboratory Research Reference

CJC-1295 is a synthetic peptide in the growth hormone–releasing hormone (GHRH) analogue family, engineered from the sequence of native growth-hormone–releasing hormone. It is studied in laboratory research for its interaction with the GHRH receptor and the downstream stimulation of growth hormone secretion in experimental models.

The "with DAC" designation refers to the covalent attachment of a Drug Affinity Complex (DAC) moiety — a chemical group that binds reversibly to albumin and markedly extends the peptide’s circulating duration. This distinguishes CJC-1295 with DAC from the shorter-acting, unmodified form described on a separate reference page.

This page is a non-promotional scientific reference for researchers. It does not provide performance, anti-ageing, therapeutic, or human-use guidance. CJC-1295 with DAC supplied by Bulk Aussie Peptides is for laboratory research purposes only.

Chemical Identity and the DAC Modification

CJC-1295 is a GHRH analogue in which the native hormone’s sequence has been modified — typically including a substitution at the albumin-binding region — to alter its pharmacokinetic behaviour. The defining feature of the "with DAC" form is the Drug Affinity Complex, which promotes reversible albumin binding and gives the peptide a long half-life in experimental models.

This distinction is functionally significant in research: the DAC form provides prolonged receptor exposure, whereas the without-DAC form is characterised by a shorter circulating duration. The two are treated as separate compounds in the literature and compared in a dedicated comparison.

Molecular Characteristics

• Classification: a growth hormone–releasing hormone (GHRH) analogue with an albumin-binding DAC moiety.
• Structural modification: DAC attachment supports albumin binding and extended duration.
• Molecular weight: reported in Daltons (Da); the measured value is compared against the theoretical mass derived from the sequence including the DAC group.
• Physical form: lyophilised (freeze-dried) powder.

Mechanism as Studied

In laboratory models, CJC-1295 with DAC binds to the GHRH receptor and promotes the release of growth hormone. Because the DAC group extends its circulating duration, it is used to study sustained GHRH-receptor activation over prolonged time courses — a distinction from unmodified and shorter-acting GHRH analogues. These findings remain preclinical.

Areas of Scientific Research

• GHRH receptor pharmacology: sustained activation and downstream signalling.
• Growth hormone secretion: pulsatile release in experimental models.
• Pharmacokinetic behaviour: the effect of the DAC albumin-binding group on circulating duration.

These investigations are conducted in vitro or in approved animal research models under institutional oversight.

Analytical Testing

CJC-1295 with DAC is characterised using:

• HPLC for purity assessment.
• Mass spectrometry for identity confirmation, including the DAC-modified mass.

See how to read a peptide Certificate of Analysis for interpretation guidance.

References and Further Reading

• CJC-1295 with DAC and the GHRH analogue family. (Preclinical research literature on growth-hormone–releasing hormone analogues.)
• CJC-1295 DAC vs No DAC — a detailed comparison.
• Reading a Peptide Certificate of Analysis.